Takeda Lifts FY2026 Outlook as H1 Operating Profit Jumps 60%
TAK sits 55% above its 52-week low of $12.99.
Summary
Takeda reported FY2026 first-half revenue of 2,407.0 billion yen, up 8.4% on an actual-exchange-rate basis but down 1.0% at constant currencies — the entire top-line gain is FX, not underlying growth. Core operating profit rose 11.2% AER but only 0.7% CER, and core EPS of 308 yen was up 10.5% AER and down 1.2% CER. Reported operating profit jumped 60.4% AER to 406.7 billion yen, largely because VYVANSE intangible amortization ended and impairment charges fell — a low-quality beat. The company raised its FY2026 forecast mainly on FX: revenue to 4,700.0 billion yen from 4,640.0, operating profit to 453.0 billion from 420.0, and EPS to 131 yen from 104. Adjusted free cash flow fell 38% to 325.7 billion yen, a soft spot. The launch story is real — ORZEYFUL is live in Japan and China with the U.S. launch awaiting DEA scheduling expected early November, MIMRYLO launched in the U.S. in August, and zasocitinib is under FDA Priority Review — but the CER guidance still calls for a mid-single-digit core operating profit decline. The investor call is today at 6:00 U.S. Eastern, and a Capital Markets Day is set for December.
At the time of this announcement, TAK was trading at $20.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $63.8B. The 52-week trading range was $12.99 to $20.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.